US OptionsDetailed Quotes
ACHV240816C2500
- 2.65
- +0.45+20.45%
15min DelayClose Jul 23 15:59 ET
2.65High2.65Low
2.65Open2.20Pre Close2 Volume6 Open Interest2.50Strike Price530.00Turnover335.01%IV0.19%PremiumAug 16, 2024Expiry Date2.64Intrinsic Value100Multiplier24DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.8982Delta0.0401Gamma1.73Leverage Ratio-0.0166Theta0.0011Rho1.55Eff Leverage0.0024Vega
Achieve Life Stock Discussion
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...
No comment yet